The clinical significance of the tumor cell D2-40 immunoreactivity in non-small cell lung cancer
- 31 October 2010
- journal article
- Published by Elsevier BV in Lung Cancer
- Vol. 70 (1), 88-93
- https://doi.org/10.1016/j.lungcan.2009.12.014
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Tailor-made chemotherapy for non-small cell lung cancer patientsFuture Oncology, 2006
- Lymphangiogenesis Correlates with Lymph Node Metastasis, Prognosis, and Angiogenic Phenotype in Human Non–Small Cell Lung CancerClinical Cancer Research, 2005
- Clinical application of biological markers for treatments of resectable non-small-cell lung cancersBritish Journal of Cancer, 2005
- A New Monoclonal Antibody, D2-40, for Detection of Lymphatic Invasion in Primary TumorsLaboratory Investigation, 2002
- Lymphatic Metastasis in the Absence of Functional Intratumor LymphaticsScience, 2002
- Lung cancer: A reviewAmerican Journal of Health-System Pharmacy, 2002
- The intratumoral expression of vascular endothelial growth factor and interleukin-8 associated with angiogenesis in nonsmall cell lung carcinoma patientsCancer, 2001
- Characterization and distribution of an oncofetal antigen (M2A antigen) expressed on testicular germ cell tumoursBritish Journal of Cancer, 1999
- Tumor Angiogenesis as a Prognostic Marker in Operable Non–Small Cell Lung CancerThe Annals of Thoracic Surgery, 1998
- What Is the Evidence That Tumors Are Angiogenesis Dependent?JNCI Journal of the National Cancer Institute, 1990